Lantheus discontinues AZEDRA production; winds down Somerset, NJ site

Lantheus Holdings, Inc.

Progenics Pharmaceuticals subsidiary to stop manufacturing and promoting AZEDRA.
Limited usage and fixed costs made continued production untenable.
Goal to supply current patients through Q1 2024 to complete treatment.
Somerset, NJ manufacturing site being wound down.
No financial impact or restructuring charges disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.